The company offers regenerative dermal and soft tissue fillers, 3D-bioprinted regenerative breast implants, and wound care products including VergenixSTR and VergenixFG. The platform leverages plant-based collagen production, creating a differentiated technology moat in the regenerative medicine space.
Cyborg Score Rationale
CollPlant faces significant headwinds: micro-cap valuation ($25M market cap), depressed stock price, low liquidity, and negative sentiment in early June 2026. Limited recent revenue data and emerging technology face regulatory and commercialization risks inherent to regenerative medicine.
Top Insights
Plant-based recombinant collagen technology differentiates from animal-derived competitors and synthetic alternatives
Multi-product portfolio spans aesthetics (fillers, implants) and therapeutic (wound care, tissue repair), providing diversification
Micro-cap valuation and low trading volume indicate limited institutional coverage and liquidity risk
Headquarters in Israel with operations in US, Canada, and Europe positions company for both Israeli and global markets
Named Competitors
Bioprinting Solutions — 3D bioprinting technology for tissue engineering
Regenerative Products — Tissue regeneration and wound care therapies
Dermal Fillers — Aesthetic medicine dermal filler products
Recent Developments
Q4 2025 earnings release projected for April 2026
Stock trading significantly below 52-week highs (52-week range $0.27–$5.55 as of early 2026)
Increased short interest reported (up 61.54% in recent months as of June 2026)
Open the full interactive CollPlant Biotechnologies Ltd report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.